Patient characteristics
| . | Matched unrelated (n = 81) . | Mismatched unrelated (n = 58) . | Haploidentical (n = 48) . | P . |
|---|---|---|---|---|
| Sex, M/F | 42/39 | 34/24 | 27/21 | .66 |
| Median age (range) | 20 (0-57) | 17 (1-57) | 22 (0-56) | .85 |
| CMV status (D/R, %) | ||||
| Neg/Neg | 29 (36) | 26 (45) | 13 (27) | .0003 |
| Pos/Neg | 22 (27) | 16 (28) | 9 (19) | |
| Neg/Pos | 23 (28) | 8 (14) | 6 (13) | |
| Pos/Pos | 7 (9) | 8 (14) | 20 (42) | |
| Disease (%) | ||||
| AML | 18 (22) | 15 (26) | 9 (19) | .13 |
| ALL | 20 (25) | 24 (41) | 23 (48) | |
| CML | 21 (26) | 12 (21) | 9 (19) | |
| MDS | 9 (11) | 2 (3) | 2 (4) | |
| Secondary AML | 8 (10) | 5 (9) | 2 (4) | |
| NHL | 5 (6) | 0 | 3 (6) | |
| Risk group (%) | ||||
| Low | 43 (53) | 25 (43) | 17 (35) | .17 |
| High | 38 (47) | 33 (57) | 31 (65) | |
| T-cell depletion (%) | ||||
| T10B9 | 60 (74) | 48 (83) | 40 (83) | .33 |
| OKT3 | 21 (26) | 10 (17) | 8 (17) | |
| Growth factor therapy (%) | ||||
| Yes | 43 (53) | 20 (34) | 40 (83) | < .0001 |
| No | 38 (47) | 38 (66) | 8 (17) | |
| CD34 cell dose × 106(range)* | 2.2 (0.5-19.2) | 1.6 (0.5-8.9) | 1.6 (0.2-5.1) | .015 |
| . | Matched unrelated (n = 81) . | Mismatched unrelated (n = 58) . | Haploidentical (n = 48) . | P . |
|---|---|---|---|---|
| Sex, M/F | 42/39 | 34/24 | 27/21 | .66 |
| Median age (range) | 20 (0-57) | 17 (1-57) | 22 (0-56) | .85 |
| CMV status (D/R, %) | ||||
| Neg/Neg | 29 (36) | 26 (45) | 13 (27) | .0003 |
| Pos/Neg | 22 (27) | 16 (28) | 9 (19) | |
| Neg/Pos | 23 (28) | 8 (14) | 6 (13) | |
| Pos/Pos | 7 (9) | 8 (14) | 20 (42) | |
| Disease (%) | ||||
| AML | 18 (22) | 15 (26) | 9 (19) | .13 |
| ALL | 20 (25) | 24 (41) | 23 (48) | |
| CML | 21 (26) | 12 (21) | 9 (19) | |
| MDS | 9 (11) | 2 (3) | 2 (4) | |
| Secondary AML | 8 (10) | 5 (9) | 2 (4) | |
| NHL | 5 (6) | 0 | 3 (6) | |
| Risk group (%) | ||||
| Low | 43 (53) | 25 (43) | 17 (35) | .17 |
| High | 38 (47) | 33 (57) | 31 (65) | |
| T-cell depletion (%) | ||||
| T10B9 | 60 (74) | 48 (83) | 40 (83) | .33 |
| OKT3 | 21 (26) | 10 (17) | 8 (17) | |
| Growth factor therapy (%) | ||||
| Yes | 43 (53) | 20 (34) | 40 (83) | < .0001 |
| No | 38 (47) | 38 (66) | 8 (17) | |
| CD34 cell dose × 106(range)* | 2.2 (0.5-19.2) | 1.6 (0.5-8.9) | 1.6 (0.2-5.1) | .015 |
Percentages do not always total 100 due to rounding.
D/R indicates donor/recipient; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplasia; and NHL, non-Hodgkin lymphoma.
CD34 cell dose data were not routinely collected on patients prior to September 1994. CD34 cell dose data presented above were therefore obtained from 60/81 (74%) matched unrelated, 37/58 (64%) mismatched unrelated, and 36/48 (75%) haploidentical marrow transplant recipients.